# V1 Empirics Check — moonshotai/kimi-k2.5 (Variant A)

**Model:** moonshotai/kimi-k2.5
**Variant:** A
**Date:** 2026-03-24T21:54:28.453302

---

 **Referee Report: "The Pill Pipeline Mirage"**

---

### 1. Idea Fidelity

The submitted paper represents a **major and unexplained deviation** from the original research design outlined in the manifest. The manifest proposed a clean causal identification strategy exploiting quasi-random assignment of disability appeals to Administrative Law Judges (ALJs) within hearing offices, using ALJ leniency as an instrumental variable (IV) for county-level SSDI/SSI enrollment. The core elements of that design—county-level ARCOS pill shipment data (2006–2014), the 24-month Medicare waiting period for SSDI versus immediate Medicaid for SSI as a timing test, and the first-stage F-statistics leveraging within-office ALJ variation—are entirely absent from the executed paper.

Instead, the authors substitute a state-year panel (2015–2022) with fixed effects and a "difference-in-drugs" correlational design. This shift abandons the IV strategy that was the project's central innovation and empirical contribution. While the paper tests a related hypothesis—whether disability prevalence correlates with opioid mortality by drug type—it does so with a research design incapable of establishing the causal claims implied by the original "pill pipeline" framing. The temporal shift to 2015–2022 (the fentanyl era) also fundamentally alters the research question: the original proposal focused on the prescription opioid wave (2006–2014) where the insurance mechanism would plausibly operate, whereas the current period is dominated by illicit supply that severs the hypothesized causal chain *by construction*.

---

### 2. Summary

Using a state-year panel from 2015–2022 linking CDC Vital Statistics Rapid Release mortality data to American Community Survey disability prevalence, the paper tests whether disability enrollment drives opioid deaths through insurance-mediated prescribing. The authors document that cross-sectional correlations between disability and mortality reverse sign (from positive to negative) upon adding state and year fixed effects. A placebo test reveals that disability prevalence negatively predicts deaths from illicit substances (fentanyl, cocaine) with similar magnitude as prescription opioid deaths, leading the authors to conclude that common economic confounds—not an insurance "pipeline"—drive the correlation. The paper argues the disability-opioid relationship is a "mirage" reflecting shared determinants of despair rather than a causal pathway.

---

### 3. Essential Points

**1. Abandonment of Causal Identification Without Justification.**  
The paper's central weakness is the substitution of the proposed ALJ leniency IV with a state-year OLS model. The manifest explicitly promised an IV design with "F >> 100" to isolate exogenous variation in disability receipt. The current design cannot distinguish causal effects from reverse causality, omitted variables (e.g., state-specific Medicaid expansion effects, naloxone distribution policies), or measurement error. The "difference-in-drugs" placebo is ingenious but insufficient: it tests whether the *mechanism* is insurance-mediated prescribing, but it does not solve the endogeneity of *disability prevalence itself*. The negative coefficients in Table 2 are consistent with unobserved state-level health investments that simultaneously reduce mortality and increase disability reporting (e.g., better diagnostic access), not merely with "confounding." Without the IV, the paper cannot credibly claim to have rejected the causal hypothesis, only that the cross-sectional correlation is not robust to state fixed effects. This is a much weaker contribution than the causal estimate originally proposed.

**2. Ecological Fallacy and Temporal Misalignment.**  
The aggregation to state-year observations (N=261) discards the geographic variation (hearing office to county) that was the empirical foundation of the original design. Disability adjudication happens at the ALJ level; mortality and prescribing happen locally. State-level disability rates are 5-year rolling averages from the ACS, smoothed and lagged, poorly suited to capture the annual fluctuations in mortality driven by fentanyl supply shocks. The low within-$R^2$ values (0.09 in Table 2, column 4) indicate the model explains almost none of the within-state temporal variation, rendering the negative point estimates noisy and potentially spurious. The paper cannot test the 24-month SSDI waiting period mechanism—a key falsification test in the manifest—because it lacks variation in *enrollment timing* and uses a period when fentanyl deaths dominate.

**3. Sample Period Mismatch with Research Question.**  
The manifest focused on 2006–2014 to test the "pill pipeline" during the prescription opioid era when ARCOS data on pill shipments were available. By switching to 2015–2022 (VSRR mortality data), the paper tests a different question: whether disability predicts mortality in the fentanyl era. The null result may simply reflect that the mechanism (insurance → prescribing → pills) was severed by the 2013–2014 shift to illicit fentanyl, not that the mechanism never existed. The paper finds a positive coefficient pre-2019 (Table 4, col. 5) and negative post-2019 (col. 6), but interprets this as the fentanyl wave "overwhelming" the channel. This is post-hoc theorizing; the original design would have tested the mechanism directly during the period when it was plausibly active.

---

### 4. Suggestions

**Reframe or Implement the Original Design.**  
If the ALJ disposition data are unavailable or lack geographic identifiers for the necessary period, the authors should state this explicitly and reframe the paper as a descriptive analysis of ecological correlations, removing causal language from the title and abstract. Alternatively, if the data are accessible, the authors should implement the IV strategy as proposed: link hearing offices to counties, construct the leave-one-out ALJ leniency instrument, and estimate the effect on county-level ARCOS shipments (2006–2014) and Medicare Part D prescribing. This would provide the credible causal evidence the manifest promised and that the literature lacks.

**Address Measurement Error in Disability Prevalence.**  
The ACS 5-year rolling average is a poor proxy for annual disability *enrollment* (the policy variable of interest). It measures stock prevalence, not flow incidence, and includes non-enrollees. If the paper remains at the state level, the authors should at least use the annual SSA state-level award data (which exists) or acknowledge that measurement error biases coefficients toward zero, complicating the interpretation of null results.

**Strengthen the Placebo Logic.**  
The "difference-in-drugs" design is the paper's most novel element. To strengthen it, the authors should explicitly model why economic confounders (e.g., deindustrialization) would affect fentanyl and cocaine deaths similarly. For example, construct an index of "deaths of despair" (liver disease, suicide) as a placebo outcome—if disability predicts these similarly to fentanyl deaths, the common-cause story strengthens. Conversely, if disability specifically predicts prescription opioid deaths but not other deaths of despair, the insurance channel survives.

**Use Medicare Part D Data Directly.**  
The manifest cited CMS Medicare Part D prescriber data. The current paper relies solely on mortality, a distal outcome contaminated by fentanyl adulteration and supply shocks. Using Part D data to examine prescribing *volume* by disability status (even at the state level) would provide a more direct test of the "pill pipeline" mechanism and align with the original proposal.

**Clarify the Mechanism for Negative Coefficients.**  
The negative within-state association (Table 2, col. 4) warrants explanation. Could it reflect that states expanding disability screening simultaneously implemented prescription drug monitoring programs (PDMPs) or Medicaid managed care restrictions? Or that the ACA's Medicaid expansion (2014) simultaneously increased disability reporting and treatment access? Explore these institutional confounders rather than attributing the sign flip solely to "between-state sorting."

**Clustering and Inference.**  
With only 41 states, clustering standard errors at the state level yields only 40 clusters. The paper should use wild cluster bootstrap or report effective degrees of freedom adjustments. The current $p$-values may be anti-conservative.

**Data Transparency.**  
Given the autonomous generation of this paper, provide a detailed data appendix verifying the merge between VSRR and ACS (e.g., how 5-year ACS estimates were assigned to single years) and confirming the exclusion of states with suppressed death counts. The VSRR data have known reporting lags and suppression rules that vary by state and year; address whether this introduces selection bias.

**Final Note.**  
The paper tackles an important policy question with a clever placebo design, but as currently executed, it answers a different question than the one proposed and uses methods insufficient for the causal claims implied. For *AER: Insights*, the bar for identification is high; this manuscript requires either the implementation of the ALJ IV strategy or a fundamental reframing as a descriptive analysis testing for ecological confounding, with correspondingly modest conclusions.
